Multiple early factors anticipate post-acute COVID-19 sequelae
Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa · Institute for Systems Biology · +18 more institutions
Abstract
T cells exhibited unique dynamics during recovery from COVID-19. Analysis of symptom-associated immunological signatures revealed coordinated immunity polarization into four endotypes, exhibiting divergent acute severity and PASC. We find that immunological associations between PASC factors diminish over time, leading to distinct convalescent immune states. Detectability of most PASC factors at COVID-19 diagnosis emphasizes the importance of early disease measurements for understanding emergent chronic conditions and suggests PASC treatment strategies.
Citation impact
- FWCI
- 140.23
- Percentile
- 100%
- References
- 87
Authors
73- YSYapeng SuCorresponding
Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa, Institute for Systems Biology, Fred Hutch Cancer Center
- DYDan Yuan
University of Washington, Institute for Systems Biology
- DCDaniel Chen
University of Washington, Institute for Systems Biology
- RTRaymond T. Ng
University of Washington, Institute for Systems Biology
- KWKai Wang
Institute for Systems Biology
Topics & keywords
- Convalescence
- Biology
- Coronavirus disease 2019 (COVID-19)
- Immune system
- Virus
- Disease
- Immunology
- Virology
- Good health and well-being
Funding
- UDU.S. Department of DefenseAward: W911NF-17-2-0086
- BABill and Melinda Gates FoundationAwards: OPP1032317, R21 AI138258, AI068129
- MMM.J. Murdock Charitable Trust
- ELEli Lilly and Company
- MMerck
- GSGilead Sciences
- CCelgene
- TPTakeda Pharmaceuticals U.S.A.
- CBCSL Behring
- AWAmazon Web Services
- PIParker Institute for Cancer Immunotherapy
- ISIstituto Superiore di Sanità
- DDDasman Diabetes Institute
- NINational Institutes of Health
- H2Horizon 2020 Framework Programme
- BABiomedical Advanced Research and Development AuthorityAward: HHSO10201600031C
- JTJuno Therapeutics
- H2Horizon 2020
- JPJanssen Pharmaceuticals
- HMH2020 Marie Skłodowska-Curie ActionsAward: 754432